Ajit Pal Singh
- Assistant Professor, Department of Medical Lab Technology Sharda School of Allied Health and Sciences, Sharda University, Gr. Noida Uttar Pradesh India
Abstract
The Human Immunodeficiency Virus (HIV), which targets immune system conductors (CD4 cells), has infected millions throughout the world. HIV lowers the body’s defences by infecting certain bodily fluids (blood, sperm, vaginal fluids, and breast milk) through unprotected sex, contaminated needles, or mother-to-child transmission. Early flu-like symptoms may go unrecognised, but if not treated, HIV advances to AIDS, which is characterised by severe immune system impairment. However, advances in antiretroviral therapy (ART) enable HIV patients to live longer lives, and PrEP medicine greatly reduces infection risk. The future of HIV prevention depends in improved education, testing, and research for vaccines and cures, as well as removing the stigma associated with the virus. Only through a concerted effort can we establish a world in which HIV infection rates fall and the virus is no longer a worldwide danger. Furthermore, tackling socioeconomic determinants of health such as poverty, gender imbalance, and stigma is critical for lowering HIV incidence and increasing the quality of life for those living with HIV.A multimodal approach is required to address the pandemic’s complex interaction of biological, social, and structural variables. This strategy should include biological treatments, behavioural interventions, and efforts to address underlying health determinants. HIV predominantly targets CD4 cells, which weakens the immune system.
Keywords: HIV/AIDS, Antiretroviral Therapy (ART), Prevention and PrEP, Socioeconomic Determinants, Immune System
[This article belongs to International Journal of Virus Studies(ijvs)]
References
- Global HI. AIDS statistics—2020 fact sheet; 2020.
- Fauci AS, Lane HC, Redfield RR. Covid-19—navigating the uncharted. New England Journal of Medicine. 2020 Mar 26;382(13):1268-9.
- Paul D. The comprehensive review of antiretroviral therapy: a paradigm shift (Doctoral dissertation, Brac University).
- Rodger A, Phillips A, Lundgren J, Tao X, Shao D, Xue W, Cohen M, Chen Y, Fleming T. Prevention of HIV-1 infection with antiretroviral therapy. N Engl J Med. 2011 Nov 17;365(20):1934.
- Kjøll AJ. Targeting the ‘End of AIDS’: Historical usage of the terms ‘target’and ‘goals’ in UNAIDS reports and what it can tell us about the ‘end of AIDS’ (Master’s thesis).
- Williams J. Mass Incarceration, Prison Release and HIV Infection in Florida Counties, 2015–2019 (Doctoral dissertation, Florida Agricultural and Mechanical University).
- Adeyemi O, Lyons M, Njim T, Okebe J, Birungi J, Nana K, Mbanya JC, Mfinanga S, Ramaiya K, Jaffar S, Garrib A. Integration of non-communicable disease and HIV/AIDS management: a review of healthcare policies and plans in East Africa. BMJ global health. 2021 May 1;6(5):e004669.
- Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clinical infectious diseases. 2014 May 1;58(9):1308-11.
- Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD, HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine. 1998 Mar 26;338(13):853-60.
- Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A. A new mechanism of resistance of human immunodeficiency virus type 2 to integrase inhibitors: a 5-amino-acid insertion in the integrase C-terminal domain. Clinical Infectious Diseases. 2019 Aug 1;69(4):657-67.
| Volume | 01 |
| Issue | 01 |
| Received | April 8, 2024 |
| Accepted | May 15, 2024 |
| Published | May 27, 2024 |